Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease by Carolyn Helms | Sep 26, 2017 | Portfolio News
Cydan Raises $34 Million to Accelerate New Treatments for Rare Genetic Diseases by Carolyn Helms | Sep 17, 2017 | Portfolio News
Zavante Therapeutics Announces Agreement With NIAID to Assess ZOLYD™ for Lower Respiratory Tract Infections by Carolyn Helms | Sep 8, 2017 | Portfolio News
Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers’ Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 by Carolyn Helms | Sep 1, 2017 | Portfolio News
Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products by Carolyn Helms | Aug 29, 2017 | Portfolio News
